<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068535</url>
  </required_header>
  <id_info>
    <org_study_id>35352-A</org_study_id>
    <nct_id>NCT01068535</nct_id>
  </id_info>
  <brief_title>Early Vascular Wall Changes by Magnetic Resonance Imaging (MRI) in Metabolic Syndrome Versus Metabolically Normal Pre-Menopausal Women: A Pilot Study</brief_title>
  <official_title>Early Vascular Wall Changes by MRI in Metabolic Syndrome vs. Metabolically Normal Pre-Menopausal Women: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the vascular permeability of blood vessel walls (of&#xD;
      the carotid artery) in pre-menopausal women who have metabolic syndrome (syndrome of having&#xD;
      at least 3/5 following features- increased abdominal fat, low good cholesterol (HDL-C),&#xD;
      elevated fasting blood fats (triglycerides), elevated blood pressure, an elevated fasting&#xD;
      glucose) versus those women who are normal weight and with normal cholesterol, blood fats,&#xD;
      blood pressure, and blood sugar. We are using a novel technology to measure vascular&#xD;
      permeability known as dynamic contrast enhancement magnetic resonance imaging (DCE-MRI). The&#xD;
      primary variable is ktrans ratio which is a mathematically derived quantity obtained from&#xD;
      DCE-MRI. We are trying to identify novel markers of early atherosclerosis in young women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study involves a phone screen &amp; 2 study visits:&#xD;
&#xD;
        -  Screening visit, which includes a quick finger stick cholesterol, glucose, triglycerides&#xD;
           test (cholestech) to determine qualification, waist measurement, weight. Results are&#xD;
           provided regardless of qualification. If the volunteer qualifies, a full blood draw&#xD;
           (approximately 45cc or 3 Tablespoons) will occur. A snack is provided once blood is&#xD;
           drawn. Additional study visit procedures include a medical history questionnaire&#xD;
           including menstrual history, height &amp; weight measurement, vital signs, and waist &amp; hip&#xD;
           measurements. This study lasts up to 90 minutes.&#xD;
&#xD;
        -  MRI visit (to occur within a week of screening visit) occurs once serum pregnancy &amp;&#xD;
           creatinine results are received &amp; only if approved to continue by P.I. (e.g. negative&#xD;
           serum pregnancy and eGFR&gt;60). An IV catheter is placed in the antecubital vein to&#xD;
           administer an injection of (gadolinium) contrast medium. A coil is placed on each side&#xD;
           of the subject's neck while laying flat on a bench, with her upper body inside the MRI&#xD;
           scanner. The entire MRI procedure takes approximately 60 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ktrans of the carotid artery wall</measure>
    <time_frame>baseline</time_frame>
    <description>Ktrans is a transfer constant that is a measure of vascular permeability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>carotid artery intima-media thickness as measured by MRI</measure>
    <time_frame>baseline</time_frame>
    <description>Carotid intima-media thickness is a measure of the actual thickness of the intima and media layers of the carotid artery wall.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">43</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Women with Metabolic Syndrome</arm_group_label>
    <description>Pre-menopausal women with Metabolic Syndrome&#xD;
Age 35-50 and any 3 of the following:&#xD;
Fasting triglycerides ≥ 150 mg/dL, Waist measurement ≥ 35 inches, HDL &lt; 50mg/dL, Fasting glucose ≥ 100mg/dL but &lt;126mg/dL or Blood pressure ≥ 130/85 or taking medication to treat high blood pressure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Metabolic Syndrome (healthy) women</arm_group_label>
    <description>Non-Metabolic syndrome pre-menopausal women age 35-50&#xD;
Body Mass Index ≤ 25&#xD;
Regular menstrual cycles (occur every 24-35 days)&#xD;
Fasting glucose &lt; 100mg/dL&#xD;
HDL-C ≥ 50mg/dL&#xD;
Waist measurement ≤ 35 inches&#xD;
Fasting triglycerides &lt; 150mg/dL</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lipids, LDL-Buoyancy, Apo-B, Apo-A1 Inflammatory markers: hs-CRP, SAA, IL-6, &amp; TNF-α Vascular&#xD;
      Adhesion Markers: VCAM, sICAM&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pre-menopausal Women&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pre-menopausal women (age 35-50)&#xD;
&#xD;
               -  still having menstrual periods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of diabetes mellitus&#xD;
&#xD;
          -  History of cardiovascular disease (peripheral vascular disease, coronary artery&#xD;
             disease, cerebrovascular disease)&#xD;
&#xD;
          -  Serum creatinine &gt;1.2 mg/dL (eGFR &lt;60 ml/min.)&#xD;
&#xD;
          -  Active rheumatologic disease&#xD;
&#xD;
          -  Use of hormonal contraception*&#xD;
&#xD;
          -  Pregnant or planning a pregnancy within the next 3 months&#xD;
&#xD;
          -  Fasting triglycerides ≥ 500 mg/dL&#xD;
&#xD;
          -  Fasting LDL-C ≥ 190 mg/dL&#xD;
&#xD;
          -  Currently taking lipid lowering medications*&#xD;
&#xD;
          -  Currently taking vaso-active (blood pressure) medications*&#xD;
&#xD;
          -  Hypertension: SBP ≥ 140 and or DBP ≥90 mm Hg&#xD;
&#xD;
          -  Chronic use of aspirin (prn use is allowed)&#xD;
&#xD;
          -  Chronic use of non-steroidal anti-inflammatory medications (prn use is allowed)&#xD;
&#xD;
          -  Tobacco use within 3 months of starting study&#xD;
&#xD;
          -  Participation in another clinical trial within the last 30 days&#xD;
&#xD;
          -  MRI specific exclusion criteria:&#xD;
&#xD;
               -  History of claustrophobia&#xD;
&#xD;
               -  History of decrease in kidney function (eGFR &lt;60 ml/min.)&#xD;
&#xD;
               -  History of reaction to a contrast medium or dye used for an MRI, CT Scan, or&#xD;
                  X-ray&#xD;
&#xD;
               -  History of significant anemia or other blood disease&#xD;
&#xD;
               -  History of seizures&#xD;
&#xD;
               -  MRI-incompatible metal such as internal metal hardware or devices * Drugs within&#xD;
                  the following classifications are exclusionary: Antilipemics, antilipidemics,&#xD;
                  beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, calcium&#xD;
                  channel blockers, alpha blockers, nitrates, and all hormonal contraceptives&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pathmaja Paramsothy, M.D.,M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harborview/University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2010</study_first_posted>
  <last_update_submitted>September 12, 2012</last_update_submitted>
  <last_update_submitted_qc>September 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolic syndrome</keyword>
  <keyword>MetS</keyword>
  <keyword>premenopausal women</keyword>
  <keyword>vascular risk</keyword>
  <keyword>atherosclerosis detection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

